Penumbra – Pioneer in Aspiration

From the original Penumbra System in 2008 to today’s RED Reperfusion Catheters, Penumbra has driven the management of Large Vessel Occlusions forward in constant technological innovation. Through continuing to support clinical studies, Penumbra is helping to ensure new technologies are available to patients around the world.

Contact Us To Learn More

DESIGNED TO ENHANCE DELIVERY IN TORTUOSITY

See how RED Reperfusion Catheters with enhanced distal hydrophilic coating are designed for smooth trackability.

The Difference in Daily Practice​

Hear Dr Donald Frei, MD, share insights about the difference REDglide Technology brings to his daily practice. In conversation with Joan Kristensen, Vice President & Head of EMEA, Penumbra.

True Lumen When You Need It!​

RED 62 delivers powerful aspiration for optimised performance in challenging anatomies. See how enhanced pushability and smooth trackability redefine boundaries.

RED 62 Reperfusion Catheter

  • 1.57 mm (.062″) Lumen: Delivers powerful aspiration 
  • 1.93mm (.076″) Outer Diameter: Low profile for easy access 
  • Atraumatic Design: Engineered to effortlessly navigate tortuous anatomy 
  • 138 cm Length: To reach target vessel 
  • 11 material transitions: Optimised for performance in complex distal anatomy
Penumbra – Pioneer in Aspiration

RED 68 Reperfusion Catheter

  • 1.73 mm (.068″) Lumen: Delivers powerful aspiration 
  • 2.13 mm (.084″) Outer Diameter: Atraumatic tip designed for improved navigation 
  • REDglide Coating: Enhanced distal hydrophilic coating for smooth trackability 
  • 132 cm Length: To reach target vessel 
  • 16 material transitions: Optimised for performance in challenging anatomy
Penumbra – Pioneer in Aspiration

RED 72 Reperfusion Catheter

  • 1.83 mm (.072″) Lumen: Delivers highest TRFa
  • 2.16 mm (.085″) Outer Diameter: Articulating marker band designed to improve tip softness 
  • REDglide Coating: Enhanced distal hydrophilic coating for smooth trackability 
  • 132 cm Length: To reach target vessel 
  • 20 material transitions: Optimised for performance in challenging anatomy 

a. As compared to AXS Vecta™ 71 and Stryker® (Medela), React™ 71 and Riptide™, AXS Vecta 74 and Stryker (Medela). Thrombus Removal Force (TRF) = (Catheter Tip Area) × (Vacuum). Sources: company website, marketing literature, IFU, and data on file.

Request More Information
Penumbra – Pioneer in Aspiration

Risk Information

Caution: Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use.

PENUMBRA SYSTEM – Intended Use
The PENUMBRA System is intended to remove thrombus and restore blood flow in the neurovasculature using aspiration.
Potential Adverse Events
Possible complications include, but are not limited to, the following:
allergic reaction and anaphylaxis from contrast media or device material; acute vessel occlusion; air embolism; arrhythmia; arteriovenous fistula; death; foreign body embolization; emboli; pseudoaneurysm; hematoma or hemorrhage at access site; residual thrombus due to inability to completely remove thrombus; infection; inflammation; intracranial hemorrhage; ischemia; renal impairment or acute renal failure from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure.

PENUMBRA SYSTEM – Intended Use
The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using continuous aspiration.

Potential Adverse Events
Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media; acute occlusion; air embolism; arteriovenous fistula; death; device malfunction; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at access site; inability to completely remove thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure.

PENUMBRA ENGINE – Intended Use
The PENUMBRA ENGINE is intended as a vacuum source for Penumbra Aspiration Systems.

Copyright© 2022 Penumbra, Inc. All rights reserved. The Penumbra P logo, Penumbra RED, and Penumbra ENGINE are registered trademarks or trademarks of Penumbra, Inc. in the USA and other countries. All other trademarks are the property of their respective owners. 25607, Rev. A 12/22 OUS